Core Insights - Edwards Lifesciences reported over $6 billion in revenue for the full year 2025, primarily driven by strong demand for its transcatheter aortic valve replacement (TAVR) products and a 56.4% growth in its transcatheter mitral and tricuspid therapies (TMTT) portfolio, despite missing analysts' earnings per share (EPS) estimates in Q4 [1][2][7] Revenue Performance - The revenue for 2025 reflects an 11.5% increase compared to 2024, with Q4 2025 revenue reaching $1.56 billion, marking a 13.3% rise from Q4 2024 [2] - The TAVR portfolio contributed $4.49 billion to total revenue in 2025, a 9.3% increase from $4.10 billion in 2024 [3] - TMTT revenue grew 56.4% to $550.6 million in 2025, up from $352.1 million in 2024 [4] - The surgical structural heart portfolio surpassed $1 billion in revenue for 2025, generating $253.6 million in Q4, with year-over-year increases of 4.9% and 3.8% respectively [5] Market Reaction - Following the financial results released after market close on February 10, the company's shares rose by 3% in after-hours trading on the New York Stock Exchange (NYSE) [3] Future Guidance - Edwards expects 2026 earnings to be in the range of $2.90 to $3.05 per share, with revenue growth guidance set between 8% and 10% at constant currency [2] - CEO Bernard Zovighian emphasized significant advancements in TMTT therapies, including the launch of SAPIEN M3 and the scaling of EVOQUE, with a revenue expectation of $2 billion for TMTT by 2030 [4][5] Earnings Analysis - Total Q4 revenue was $1.56 billion, with the TAVR portfolio accounting for $1.16 billion, a 12% increase from approximately $1 billion in Q4 2024, exceeding analysts' estimates of $1.13 billion [6] - Adjusted EPS for Q4 was $0.58, falling short of the $0.62 estimate, attributed to a deliberate increase in spending ahead of improving TAVR guidelines and potential expanded reimbursement in 2026 [7]

Industry Overview - The MedTech industry has demonstrated resilience and steady growth through 2025, with the Dow Jones U.S. Select Medical Equipment Index advancing about 8% in 2025, indicating the sector's adaptability and consistent performance despite challenges [1] - The MedTech market was valued at $549.51 billion in 2025 and is projected to reach $853.37 billion by 2035, with a CAGR of 4.5% [5] Growth Drivers for 2026 - Improving fundamentals in the MedTech industry are expected to drive growth in 2026, as procedure volumes normalize and healthcare providers prioritize technologies that enhance clinical outcomes and operational efficiency [2] - The expanding role of artificial intelligence and data-driven solutions is anticipated to be a key growth driver, with the global AI in healthcare market projected to grow from $26.57 billion in 2024 to $505.59 billion by 2033, reflecting a CAGR of 38.81% from 2025 to 2033 [3] - Continued momentum in minimally invasive and robotics-assisted procedures is expected to support MedTech growth, with the global minimally invasive surgery market projected to grow from $94.45 billion in 2025 to $199.3 billion by 2030, reflecting a CAGR of 16.1% [4] Company-Specific Insights Cardinal Health (CAH) - Cardinal Health is a leading healthcare services and products company with a market capitalization of around $48 billion, focusing on pharmaceuticals and medical supplies distribution [6] - The company is positioned for growth in 2026, benefiting from disciplined cost management, pricing actions, and normalization of volumes, with an earnings growth rate for fiscal 2026 pegged at 19.7% [7][9] - CAH's stock has surged more than 71% year-to-date, with a projected revenue increase of 16.2% year-over-year for fiscal 2026 [9] Medtronic (MDT) - Medtronic is a diversified global leader in medical technology, with a strong portfolio across various health conditions and a large installed base [10] - The company reported a revenue increase of approximately 5.5% organically in its latest results, driven by double-digit growth in cardiac ablation solutions [11] - MDT's stock has improved 23.5% year-to-date, with a projected revenue increase of 7.5% year-over-year for fiscal 2026 [12] Intuitive Surgical (ISRG) - Intuitive Surgical is the leader in robotic-assisted minimally invasive surgery, known for its da Vinci Surgical System [13] - The company is poised for growth in 2026 as robotic surgery adoption expands, with an earnings growth rate for 2026 estimated at 11.2% and a projected revenue increase of 14.3% year-over-year [15] - ISRG's stock has grown by 9.7% year-to-date [15] Edwards Lifesciences (EW) - Edwards Lifesciences focuses on structural heart disease and critical care technologies, with a strong reputation in transcatheter aortic valve replacement [16] - The company is expected to benefit from the growing adoption of TAVR procedures, with an earnings growth rate for 2026 estimated at 10.4% and a projected revenue increase of 9.6% year-over-year [18] - EW's stock has improved more than 15% year-to-date [18]